Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20958454 | 1.00 | NAAA (0.51) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL20958452 | 1.00 | NAAA (0.51) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL1165321 | 1.00 | NAAA (0.51) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL22866415 | 0.84 | NAAA (0.47) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL22174117 | 0.84 | NAAA (0.47) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL22866416 | 0.84 | NAAA (0.47) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL22174122 | 0.84 | NAAA (0.47) | NAAAEPHX2KCNH2OPRK1HRH3 | |
| SCHEMBL12094627 | 0.82 | GPR119 (0.61) | NAAAGPR119 | |
| SCHEMBL20958519 | 0.82 | KCNH2 (0.42) | KCNH2OPRK1GPR119 | |
| SCHEMBL20958461 | 0.81 | NAAA (0.51) | NAAAEPHX2KCNH2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865194-B2 | Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-12-15 | — | — | US | disclosed |
| US-20190135778-A1 | THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-05-09 | — | — | US | disclosed |
| WO-2011021645-A1 | BICYCLIC UREA DERIVATIVE OR PHARMACOLOGICALLY PERMITTED SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135778-A1 | THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS | NAAA, FAAH, FAAH2 | NAAA 1/4885EPHX2 434/4885KCNH2 2855/4885 |
| US-10865194-B2 | Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions | NAAA, FAAH2, FAAH | NAAA 1/4885EPHX2 183/4885KCNH2 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.